{"pmid":32472653,"title":"Cell-based therapy to reduce mortality from COVID-19: Systematic review and meta-analysis of human studies on acute respiratory distress syndrome.","text":["Cell-based therapy to reduce mortality from COVID-19: Systematic review and meta-analysis of human studies on acute respiratory distress syndrome.","Severe cases of COVID-19 infection, often leading to death, have been associated with variants of acute respiratory distress syndrome (ARDS). Cell therapy with mesenchymal stromal cells (MSCs) is a potential treatment for COVID-19 ARDS based on preclinical and clinical studies supporting the concept that MSCs modulate the inflammatory and remodeling processes and restore alveolo-capillary barriers. The authors performed a systematic literature review and random-effects meta-analysis to determine the potential value of MSC therapy for treating COVID-19-infected patients with ARDS. Publications in all languages from 1990 to March 31, 2020 were reviewed, yielding 2691 studies, of which nine were included. MSCs were intravenously or intratracheally administered in 200 participants, who were followed for 14 days to 5 years. All MSCs were allogeneic from bone marrow, umbilical cord, menstrual blood, adipose tissue, or unreported sources. Combined mortality showed a favorable trend but did not reach statistical significance. No related serious adverse events were reported and mild adverse events resolved spontaneously. A trend was found of improved radiographic findings, pulmonary function (lung compliance, tidal volumes, PaO2 /FiO2 ratio, alveolo-capillary injury), and inflammatory biomarker levels. No comparisons were made between MSCs of different sources.","Stem Cells Transl Med","Qu, Wenchun","Wang, Zhen","Hare, Joshua M","Bu, Guojun","Mallea, Jorge M","Pascual, Jorge M","Caplan, Arnold I","Kurtzberg, Joanne","Zubair, Abba C","Kubrova, Eva","Engelberg-Cook, Erica","Nayfeh, Tarek","Shah, Vishal P","Hill, James C","Wolf, Michael E","Prokop, Larry J","Murad, M Hassan","Sanfilippo, Fred P","32472653"],"abstract":["Severe cases of COVID-19 infection, often leading to death, have been associated with variants of acute respiratory distress syndrome (ARDS). Cell therapy with mesenchymal stromal cells (MSCs) is a potential treatment for COVID-19 ARDS based on preclinical and clinical studies supporting the concept that MSCs modulate the inflammatory and remodeling processes and restore alveolo-capillary barriers. The authors performed a systematic literature review and random-effects meta-analysis to determine the potential value of MSC therapy for treating COVID-19-infected patients with ARDS. Publications in all languages from 1990 to March 31, 2020 were reviewed, yielding 2691 studies, of which nine were included. MSCs were intravenously or intratracheally administered in 200 participants, who were followed for 14 days to 5 years. All MSCs were allogeneic from bone marrow, umbilical cord, menstrual blood, adipose tissue, or unreported sources. Combined mortality showed a favorable trend but did not reach statistical significance. No related serious adverse events were reported and mild adverse events resolved spontaneously. A trend was found of improved radiographic findings, pulmonary function (lung compliance, tidal volumes, PaO2 /FiO2 ratio, alveolo-capillary injury), and inflammatory biomarker levels. No comparisons were made between MSCs of different sources."],"journal":"Stem Cells Transl Med","authors":["Qu, Wenchun","Wang, Zhen","Hare, Joshua M","Bu, Guojun","Mallea, Jorge M","Pascual, Jorge M","Caplan, Arnold I","Kurtzberg, Joanne","Zubair, Abba C","Kubrova, Eva","Engelberg-Cook, Erica","Nayfeh, Tarek","Shah, Vishal P","Hill, James C","Wolf, Michael E","Prokop, Larry J","Murad, M Hassan","Sanfilippo, Fred P"],"date":"2020-05-31T11:00:00Z","year":2020,"_id":"32472653","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1002/sctm.20-0146","keywords":["covid-19","acute respiratory distress syndrome","mesenchymal stromal cells","mortality","systematic review"],"topics":["Treatment"],"weight":1,"_version_":1668255193447268353,"score":9.490897,"similar":[{"pmid":32292627,"pmcid":"PMC7102606","title":"Clinical study of mesenchymal stem cell treating acute respiratory distress syndrome induced by epidemic Influenza A (H7N9) infection, a hint for COVID-19 treatment.","text":["Clinical study of mesenchymal stem cell treating acute respiratory distress syndrome induced by epidemic Influenza A (H7N9) infection, a hint for COVID-19 treatment.","H7N9 viruses quickly spread between mammalian hosts, and it carried out the risk of human-to-human transmission after outbreak in 2013. Acute respiratory distress syndrome (ARDS), lung failure, and fulminant pneumonia are major lung diseases in H7N9 patients. Transplantation of mesenchymal stem cells (MSCs) is a promising choice for treating virus-induced pneumonia, and was needed to treat H7N9 induced ARDS at the time. MSCs transplant into patients with H7N9 induced ARDS were conducted in a single center and open-label clinical trial. Based on the principle of voluntariness and informed consent, 44 patients with H7N9 induced ARDS were included as a control group while 17 patients with H7N9 induced ARDS were served as an experimental group with allogeneic menstrual blood-derived MSC. Notably, MSC transplantation significantly lower the mortality compared with in control group (17.6% died in MSC group vs 54.5% died in control group). Furthermore, MSC transplantation did not result in harmful effects in human body within the 5 year follow up period with 4 patients. Collectively, these results suggest that MSCs significantly improve survival rate of H7N9 induced ARDS and provide a theoretical basis for the treatment of H7N9 induced ARDS in both preclinical research and clinical studies. Because H7N9 and the corona virus disease 2019 (COVID-19) share similar complications (such as ARDS and lung failure) and corresponding multi-organ dysfunction, MSC-based therapy could be a possible alternative for treating COVID-19.","Engineering (Beijing)","Chen, Jiajia","Hu, Chenxia","Chen, Lijun","Tang, Lingling","Zhu, Yixin","Xu, Xiaowei","Chen, Lu","Gao, Hainv","Lu, Xiaoqing","Yu, Liang","Dai, Xiahong","Xiang, Charlie","Li, Lanjuan","32292627"],"abstract":["H7N9 viruses quickly spread between mammalian hosts, and it carried out the risk of human-to-human transmission after outbreak in 2013. Acute respiratory distress syndrome (ARDS), lung failure, and fulminant pneumonia are major lung diseases in H7N9 patients. Transplantation of mesenchymal stem cells (MSCs) is a promising choice for treating virus-induced pneumonia, and was needed to treat H7N9 induced ARDS at the time. MSCs transplant into patients with H7N9 induced ARDS were conducted in a single center and open-label clinical trial. Based on the principle of voluntariness and informed consent, 44 patients with H7N9 induced ARDS were included as a control group while 17 patients with H7N9 induced ARDS were served as an experimental group with allogeneic menstrual blood-derived MSC. Notably, MSC transplantation significantly lower the mortality compared with in control group (17.6% died in MSC group vs 54.5% died in control group). Furthermore, MSC transplantation did not result in harmful effects in human body within the 5 year follow up period with 4 patients. Collectively, these results suggest that MSCs significantly improve survival rate of H7N9 induced ARDS and provide a theoretical basis for the treatment of H7N9 induced ARDS in both preclinical research and clinical studies. Because H7N9 and the corona virus disease 2019 (COVID-19) share similar complications (such as ARDS and lung failure) and corresponding multi-organ dysfunction, MSC-based therapy could be a possible alternative for treating COVID-19."],"journal":"Engineering (Beijing)","authors":["Chen, Jiajia","Hu, Chenxia","Chen, Lijun","Tang, Lingling","Zhu, Yixin","Xu, Xiaowei","Chen, Lu","Gao, Hainv","Lu, Xiaoqing","Yu, Liang","Dai, Xiahong","Xiang, Charlie","Li, Lanjuan"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32292627","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.eng.2020.02.006","keywords":["acute respiratory distress syndrome","covid-19","epidemic influenza a","h7n9","mesenchymal stem cell","stem cell therapeutics"],"topics":["Treatment"],"weight":1,"_version_":1666138494514233344,"score":356.49533},{"pmid":32479246,"title":"Mesenchymal Stem Cell-based Therapy for COVID-19: Possibility and Potential.","text":["Mesenchymal Stem Cell-based Therapy for COVID-19: Possibility and Potential.","A novel coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has emerged in Wuhan, China since the end of December 2019 and has quickly spread all over the world in a matter of two months. To date, no specific treatment has been proven to be effective for coronavirus disease 2019 (COVID-19). With the rapid increase of infected patients and deaths, it is urgent to explore an effective treatment for COVID-19. Current studies suggest that there exists cytokine storm in SARS-CoV-2-infected patient, some of the patients will develop to acute respiratory distress syndrome (ARDS) and multiple organ dysfunction, even death. Mesenchymal stem cells (MSCs) possess the property of immunomodulation. Given the previous preclinical and clinical studies, MSCs therapy has been shown safety and efficacy in the treatment of respiratory failure or ARDS. Based on similar principles, MSCs therapy may also be an effective therapy in the treatment of COVID-19. In this study, we summarized the clinical outcomes of MSCs for ARDS patients in some preclinical and clinical studies, and discussed the application of MSCs for patients with COVID-19 in China and the related important issues with MSCs use during the outbreak.","Curr Stem Cell Res Ther","Xiong, Jing","Bao, Lei","Qi, Hongbo","Feng, Zhichun","Shi, Yuan","32479246"],"abstract":["A novel coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has emerged in Wuhan, China since the end of December 2019 and has quickly spread all over the world in a matter of two months. To date, no specific treatment has been proven to be effective for coronavirus disease 2019 (COVID-19). With the rapid increase of infected patients and deaths, it is urgent to explore an effective treatment for COVID-19. Current studies suggest that there exists cytokine storm in SARS-CoV-2-infected patient, some of the patients will develop to acute respiratory distress syndrome (ARDS) and multiple organ dysfunction, even death. Mesenchymal stem cells (MSCs) possess the property of immunomodulation. Given the previous preclinical and clinical studies, MSCs therapy has been shown safety and efficacy in the treatment of respiratory failure or ARDS. Based on similar principles, MSCs therapy may also be an effective therapy in the treatment of COVID-19. In this study, we summarized the clinical outcomes of MSCs for ARDS patients in some preclinical and clinical studies, and discussed the application of MSCs for patients with COVID-19 in China and the related important issues with MSCs use during the outbreak."],"journal":"Curr Stem Cell Res Ther","authors":["Xiong, Jing","Bao, Lei","Qi, Hongbo","Feng, Zhichun","Shi, Yuan"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32479246","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.2174/1574888X15666200601152832","keywords":["mesenchymal stem cells","acute respiratory distress syndrome","coronavirus disease 2019"],"locations":["Wuhan","China","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1668532089573605376,"score":303.1237},{"pmid":32423449,"title":"Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients.","text":["Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients.","In late 2019, a novel coronavirus (SARS-CoV-2) emerged in Wuhan, capital city of Hubei province in China. Cases of SARS-CoV-2 infection quickly grew by several thousand per day. Less than 100 days later, the World Health Organization declared that the rapidly spreading viral outbreak had become a global pandemic. Coronavirus disease 2019 (COVID-19) is typically associated with fever and respiratory symptoms. It often progresses to severe respiratory distress and multi-organ failure which carry a high mortality rate. Older patients or those with medical comorbidities are at greater risk for severe disease. Inflammation, pulmonary edema and an over-reactive immune response can lead to hypoxia, respiratory distress and lung damage. Mesenchymal stromal/stem cells (MSCs) possess potent and broad-ranging immunomodulatory activities. Multiple in vivo studies in animal models and ex vivo human lung models have demonstrated the MSC's impressive capacity to inhibit lung damage, reduce inflammation, dampen immune responses and aid with alveolar fluid clearance. Additionally, MSCs produce molecules that are antimicrobial and reduce pain. Upon administration by the intravenous route, the cells travel directly to the lungs where the majority are sequestered, a great benefit for the treatment of pulmonary disease. The in vivo safety of local and intravenous administration of MSCs has been demonstrated in multiple human clinical trials, including studies of acute respiratory distress syndrome (ARDS). Recently, the application of MSCs in the context of ongoing COVID-19 disease and other viral respiratory illnesses has demonstrated reduced patient mortality and, in some cases, improved long-term pulmonary function. Adipose-derived stem cells (ASC), an abundant type of MSC, are proposed as a therapeutic option for the treatment of COVID-19 in order to reduce morbidity and mortality. Additionally, when proven to be safe and effective, ASC treatments may reduce the demand on critical hospital resources. The ongoing COVID-19 outbreak has resulted in significant healthcare and socioeconomic burdens across the globe. There is a desperate need for safe and effective treatments. Cellular based therapies hold great promise for the treatment of COVID-19. This literature summary reviews the scientific rationale and need for clinical studies of adipose-derived stem cells and other types of mesenchymal stem cells in the treatment of patients who suffer with COVID-19.","J Transl Med","Rogers, Christopher J","Harman, Robert J","Bunnell, Bruce A","Schreiber, Martin A","Xiang, Charlie","Wang, Fu-Sheng","Santidrian, Antonio F","Minev, Boris R","32423449"],"abstract":["In late 2019, a novel coronavirus (SARS-CoV-2) emerged in Wuhan, capital city of Hubei province in China. Cases of SARS-CoV-2 infection quickly grew by several thousand per day. Less than 100 days later, the World Health Organization declared that the rapidly spreading viral outbreak had become a global pandemic. Coronavirus disease 2019 (COVID-19) is typically associated with fever and respiratory symptoms. It often progresses to severe respiratory distress and multi-organ failure which carry a high mortality rate. Older patients or those with medical comorbidities are at greater risk for severe disease. Inflammation, pulmonary edema and an over-reactive immune response can lead to hypoxia, respiratory distress and lung damage. Mesenchymal stromal/stem cells (MSCs) possess potent and broad-ranging immunomodulatory activities. Multiple in vivo studies in animal models and ex vivo human lung models have demonstrated the MSC's impressive capacity to inhibit lung damage, reduce inflammation, dampen immune responses and aid with alveolar fluid clearance. Additionally, MSCs produce molecules that are antimicrobial and reduce pain. Upon administration by the intravenous route, the cells travel directly to the lungs where the majority are sequestered, a great benefit for the treatment of pulmonary disease. The in vivo safety of local and intravenous administration of MSCs has been demonstrated in multiple human clinical trials, including studies of acute respiratory distress syndrome (ARDS). Recently, the application of MSCs in the context of ongoing COVID-19 disease and other viral respiratory illnesses has demonstrated reduced patient mortality and, in some cases, improved long-term pulmonary function. Adipose-derived stem cells (ASC), an abundant type of MSC, are proposed as a therapeutic option for the treatment of COVID-19 in order to reduce morbidity and mortality. Additionally, when proven to be safe and effective, ASC treatments may reduce the demand on critical hospital resources. The ongoing COVID-19 outbreak has resulted in significant healthcare and socioeconomic burdens across the globe. There is a desperate need for safe and effective treatments. Cellular based therapies hold great promise for the treatment of COVID-19. This literature summary reviews the scientific rationale and need for clinical studies of adipose-derived stem cells and other types of mesenchymal stem cells in the treatment of patients who suffer with COVID-19."],"journal":"J Transl Med","authors":["Rogers, Christopher J","Harman, Robert J","Bunnell, Bruce A","Schreiber, Martin A","Xiang, Charlie","Wang, Fu-Sheng","Santidrian, Antonio F","Minev, Boris R"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32423449","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1186/s12967-020-02380-2","keywords":["ards","covid-19","mesenchymal stem cells","pneumonia","sars-cov-2"],"locations":["Wuhan","Hubei","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1667352728892866562,"score":276.09363},{"pmid":32265310,"pmcid":"PMC7144273","title":"Current Status of Cell-Based Therapies for Respiratory Virus Infections: Applicability to COVID-19.","text":["Current Status of Cell-Based Therapies for Respiratory Virus Infections: Applicability to COVID-19.","Severe respiratory consequences of the COVID-19 pandemic have prompted urgent need for novel therapies. Cell-based approaches, primarily using mesenchymal stem (stromal) cells (MSCs), have demonstrated safety and possible efficacy in patients with the acute respiratory distress syndrome (ARDS), although not as yet well studied in respiratory virus-induced ARDS. Limited pre-clinical data suggest that systemic MSC administration can significantly reduce respiratory virus (Influenza strains H5N1 and H9N2)-induced lung injury, however, there are no available data in models of coronavirus respiratory infection.There are a rapidly increasing number of clinical investigations of cell-based therapy approaches for COVID-19. These utilise a range of different cell sources, doses, dosing strategies, and targeted patient populations. To provide a rationale strategy to maximise potential therapeutic use, it is critically important to understand the relevant pre-clinical studies and postulated mechanisms of MSC actions in respiratory virus-induced lung injuries. These are presented along with consideration of current clinical investigations.","Eur Respir J","Khoury, Maroun","Cuenca, Jimena","Cruz, Fernanda F","Figueroa, Fernando E","Rocco, Patricia R M","Weiss, Daniel J","32265310"],"abstract":["Severe respiratory consequences of the COVID-19 pandemic have prompted urgent need for novel therapies. Cell-based approaches, primarily using mesenchymal stem (stromal) cells (MSCs), have demonstrated safety and possible efficacy in patients with the acute respiratory distress syndrome (ARDS), although not as yet well studied in respiratory virus-induced ARDS. Limited pre-clinical data suggest that systemic MSC administration can significantly reduce respiratory virus (Influenza strains H5N1 and H9N2)-induced lung injury, however, there are no available data in models of coronavirus respiratory infection.There are a rapidly increasing number of clinical investigations of cell-based therapy approaches for COVID-19. These utilise a range of different cell sources, doses, dosing strategies, and targeted patient populations. To provide a rationale strategy to maximise potential therapeutic use, it is critically important to understand the relevant pre-clinical studies and postulated mechanisms of MSC actions in respiratory virus-induced lung injuries. These are presented along with consideration of current clinical investigations."],"journal":"Eur Respir J","authors":["Khoury, Maroun","Cuenca, Jimena","Cruz, Fernanda F","Figueroa, Fernando E","Rocco, Patricia R M","Weiss, Daniel J"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32265310","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1183/13993003.00858-2020","topics":["Treatment"],"weight":1,"_version_":1666138491957805056,"score":272.9283},{"pmid":32489692,"pmcid":"PMC7220297","title":"Adipose Stem Cells (ASCs) and Stromal Vascular Fraction (SVF) as a Potential Therapy in Combating (COVID-19)-Disease.","text":["Adipose Stem Cells (ASCs) and Stromal Vascular Fraction (SVF) as a Potential Therapy in Combating (COVID-19)-Disease.","A recent and interesting study reported improved respiratory activity after intravenous administration of mesenchymal stem cells (MSCs) into patients affected by coronavirus disease 2019 (COVID-19). These outcomes displayed that intravenous infiltration of MSCs is a safe and efficacy treatment for COVID-19 pneumonia, a severe acute respiratory illness caused by the coronavirus 2 (SARS-CoV-2). Only 7 patients were treated, but with extraordinary results, opening a new strategy in COVID-19 therapy. Currently, no specific therapies against SARS-CoV-2 are available. The MSCs therapy outcomes reported, are striking, as these cells inhibit the over-activation of the immune system, promoting endogenous repair, by improving the lung microenvironment after the SARS-CoV-2 infection. The MSCs could represent an effective, autologous and safe therapy, and therefore, sharing these published results, here is reported the potential use possibilities in COVID-19 of the most common MSCs represented by Adipose Stem Cells (ASCs).","Aging Dis","Gentile, Pietro","Sterodimas, Aris","32489692"],"abstract":["A recent and interesting study reported improved respiratory activity after intravenous administration of mesenchymal stem cells (MSCs) into patients affected by coronavirus disease 2019 (COVID-19). These outcomes displayed that intravenous infiltration of MSCs is a safe and efficacy treatment for COVID-19 pneumonia, a severe acute respiratory illness caused by the coronavirus 2 (SARS-CoV-2). Only 7 patients were treated, but with extraordinary results, opening a new strategy in COVID-19 therapy. Currently, no specific therapies against SARS-CoV-2 are available. The MSCs therapy outcomes reported, are striking, as these cells inhibit the over-activation of the immune system, promoting endogenous repair, by improving the lung microenvironment after the SARS-CoV-2 infection. The MSCs could represent an effective, autologous and safe therapy, and therefore, sharing these published results, here is reported the potential use possibilities in COVID-19 of the most common MSCs represented by Adipose Stem Cells (ASCs)."],"journal":"Aging Dis","authors":["Gentile, Pietro","Sterodimas, Aris"],"date":"2020-06-04T11:00:00Z","year":2020,"_id":"32489692","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.14336/AD.2020.0422","keywords":["adipocyte secreted exosomal microrna","covid-19","adipose derived stem cells","coronavirus","mesenchymal stem cells"],"locations":["Combating"],"topics":["Treatment"],"weight":1,"_version_":1668892169329442816,"score":253.75754}]}